$2.65 Billion is the total value of Flagship Pioneering Inc.'s 33 reported holdings in Q2 2022. The portfolio turnover from Q1 2022 to Q2 2022 was 7.7% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| MRNA | Sell | Moderna Inc | $1,840,872,000 | -39.2% | 12,886,743 | -26.7% | 69.35% | -2.5% |
| SANA | Sana Biotechnology Inc | $220,158,000 | -22.2% | 34,239,018 | 0.0% | 8.29% | +24.9% | |
| FHTX | Foghorn Therapeutics Inc | $172,368,000 | -10.7% | 12,674,120 | 0.0% | 6.49% | +43.3% | |
| EVLO | Buy | Evelo Biosciences Inc | $106,401,000 | +36.3% | 50,427,328 | +119.0% | 4.01% | +118.7% |
| Omega Therapeutics Inc | $98,428,000 | -39.1% | 25,902,269 | 0.0% | 3.71% | -2.3% | ||
| DNLI | Denali Therapeutics Inc | $77,106,000 | -8.5% | 2,619,968 | 0.0% | 2.90% | +46.8% | |
| MCRB | Seres Therapeutics Inc | $49,319,000 | -51.8% | 14,378,802 | 0.0% | 1.86% | -22.7% | |
| AXLA | Axcella Health Inc | $38,302,000 | -21.0% | 18,867,785 | 0.0% | 1.44% | +26.7% | |
| RUBY | Rubius Therapeutics Inc | $32,731,000 | -84.6% | 38,506,526 | 0.0% | 1.23% | -75.3% | |
| SGTX | Sigilon Therapeutics Inc | $8,608,000 | -43.5% | 10,370,369 | 0.0% | 0.32% | -9.5% | |
| CDAK | Codiak Biosciences Inc | $7,510,000 | -54.1% | 2,607,303 | 0.0% | 0.28% | -26.3% | |
| SYRS | Syros Pharmaceuticals Inc | $2,821,000 | -19.3% | 2,938,494 | 0.0% | 0.11% | +29.3% | |
| KLDO | Exit | Kaleido Biosciences Inc | $0 | – | -19,575,710 | -100.0% | -0.76% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
- Flagship Ventures Fund V General Partner LLC #1
- Flagship Ventures Fund IV General Partner LLC #2
- Noubar Afeyan #3
- Flagship Opportunities Fund I General Partner LLC #4
- Flagship Pioneering Special Opportunities Fund II General Partner LLC #5
- Nutritional Health Fund LTP General Partner LLC #6
- Flagship Pioneering Fund VI General Partner LLC #7
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-08-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| SERES THERAPEUTICS INC | 29 | Q3 2023 | 68.0% |
| DENALI THERAPEUTICS INC | 24 | Q3 2023 | 50.9% |
| SYROS PHARMACEUTICALS INC | 24 | Q2 2022 | 27.3% |
| MODERNA INC | 20 | Q3 2023 | 76.9% |
| EVELO BIOSCIENCES INC | 20 | Q1 2023 | 41.2% |
| RUBIUS THERAPEUTICS INC | 18 | Q4 2022 | 60.7% |
| Axcella Health Inc | 17 | Q2 2023 | 3.5% |
| KALEIDO BIOSCIENCES INC | 13 | Q1 2022 | 9.5% |
| Foghorn Therapeutics Inc | 12 | Q3 2023 | 6.5% |
| Sana Biotechnology Inc | 11 | Q3 2023 | 18.4% |
View Flagship Pioneering Inc.'s complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 4 | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 4 | 2023-09-15 |
| 4 | 2023-08-15 |
| 13F-HR | 2023-08-14 |
| 4 | 2023-07-13 |
| 13F-HR | 2023-05-15 |
| 4 | 2023-02-27 |
| 13F-HR | 2023-02-14 |
View Flagship Pioneering Inc.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.